AGIO Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 1.4%, SMA50 2.58%, SMA200 -17.65%). The stock’s 14-day RSI is 52.24 (neutral), while the ATR of 1.26 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -38.98% below its high and over 26.21% above its low. Average 10-day trading volume of 866.70 thousand shares is below the 3-month average of 1.64 million, indicating normal recent market interest.

Agios Pharmaceuticals, Inc. has 58.31 million shares outstanding. The public float is 51.51 million shares, elevated short interest at 12.87% of float. This equals 7.45 million shares. The short ratio is 5.03 days. Institutional investors hold 106.44% of the float. Insiders own 1.68%. CELGENE CORP /DE/ holds 1.78 million shares, FOUSE JACQUALYN A has 149.22 thousand shares and Goff Brian has 136.58 thousand shares. Over the past six months, insider transactions show net selling. They sold 46.03 thousand shares across 15 transactions.

Agios Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$9.60. This means the shares are trading below this model’s fair value.

The latest quarter delivered EPS of -$1.78. The next quarter is forecast at -$1.95. Next year's EPS is expected at -$1.48. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 10 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $65.00 to $25.00. The high target offers 131.56% upside. The low target suggests -10.94% downside. The mean target is $41.35. This offers 47.31% upside. Agios Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended October 30, 2025, missed forecasts by -7.77%. The prior quarter beat by 10.92%. Over the last six quarters, Apple has recorded several small beats. These include 7.1% in August 01, 2024.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closed at $28.07 USD, gaining $0.36 (1.30%) from the previous close of $27.71. The stock is currently mid-range between its 52-week high and low $22.24 and $46.00. With a market capitalization of about $1.64 billion, Agios Pharmaceuticals, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.91). Key stats such as the average daily volume over the past year has been around 1.69 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Agios Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Brian Goff, the company employs approximately 486 people and listed since July 24, 2013. Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology.

Agios Pharmaceuticals, Inc. trades at a P/E ratio of -4.1, slightly below the S&P 500 average, with a price-to-sales ratio of 36.82 and a price-to-book ratio of 1.28 suggesting the stock is closer to book value. The P/FCF stands at -3.98, also above market averages.

Our AI price prediction model suggests that Agios Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.21%, with price expected at $27.45 by February 25, 2026, within a range of $26.40 to $28.50 3-Month Outlook: Projected rise of 1.85%, reaching $28.59 by May 12, 2026, with a range of $25.85 to $30.49. 1-Year Outlook: Projected gain of 8.98%, with price at $30.59 by February 11, 2027, within a range of $27.88 to $33.70.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares are flat -1.98% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Agios Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -4.1. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $51.46, suggesting 83.33% upside. Our AI forecast model points to short-term weakness (-2.21% over two weeks), a medium-term rise (1.85% over three months), and a longer-term gain (8.98% over one year), with expected trading ranges indicating moderate volatility.